ACADEMIA
Edoxaban Subgroup Analysis of East Asian Patients “Consistent” with Global Study Results: Researcher
Subgroup analysis results of East Asian populations from a global PIII study, ENGAGE AF-TIMI 48, which compared Daiichi Sankyo’s Lixiana (edoxaban) and warfarin in non-valvular atrial fibrillation (NVAF) patients, were consistent with the full results of the study, a researcher…
To read the full story
ACADEMIA
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





